INFORS HT appoints experienced business leader Peter Tunon as CEO of US subsidiary

INFORS HT, Swiss manufacturer of bioreactors, shaker incubations and bioprocess software announces that Peter Tunon as has been appointed as the new CEO for Infors USA Inc.

(PresseBox) ( Bottmingen, )
Mr. Tunon is succeeding Mr. Simon Egli, who after three years in the US is returning to the corporate headquarters Switzerland to become the new global director of sales. Over the past 30 years Peter Tunon has established himself as an expert in the commercialization of life science tools and technologies, with a focus on bioprocessing. He earned his Bachelor of Science in biochemistry from Uppsala University, Sweden and has a broad background in management with a number of companies. His experience includes tools and technologies for biological research and production, including the management of cutting edge life sciences companies. In his new role Mr. Tunon will lead the continued expansion of the of the INFORS HT brand in the USA.

“Peter brings a profound understanding of the business of life sciences and bioprocessing”, says Michael Hawrylenko, President of INFORS HT. “We are excited to have Peter in our team. He brings a wealth of experiences that will be crucial for the continued expansion of our US business.”

“I am honoured to have been give this responsibility”, explains Mr. Tunon. “INFORS HT is a very exciting company, with a strong reputation in biotechnology. I look forward to working with the US team and the Swiss headquarters to make the brand even more successful in the USA.”
The publisher indicated in each case is solely responsible for the press releases above, the event or job offer displayed, and the image and sound material used (see company info when clicking on image/message title or company info right column). As a rule, the publisher is also the author of the press releases and the attached image, sound and information material.
The use of information published here for personal information and editorial processing is generally free of charge. Please clarify any copyright issues with the stated publisher before further use. In the event of publication, please send a specimen copy to